Cargando…

The Potential Role of Biomarkers Associated with ASCVD Risk: Risk-Enhancing Biomarkers

Serum cholesterol is major risk factor and contributor to atherosclerotic cardiovascular disease (ASCVD). Therapeutic cholesterol-lowering drugs, especially statin, revealed that reduction in low-density lipoprotein cholesterol (LDL-C) produces marked reduction of ASCVD events. In the preventive sco...

Descripción completa

Detalles Bibliográficos
Autor principal:	Choi, Seonghoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Lipidology and Atherosclerosis 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379121/ https://www.ncbi.nlm.nih.gov/pubmed/32821707 http://dx.doi.org/10.12997/jla.2019.8.2.173

Ejemplares similares

Association of hyperuricemia combined with sarcopenia on ASCVD risk
por: Nie, Guqiao, et al.
Publicado: (2023)

Gauging ASCVD Risk, Does Race Matter?
por: Zuo, Ming-Liang, et al.
Publicado: (2022)

Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk
por: Rikhi, Rishi, et al.
Publicado: (2022)

A tool to help patients visualize ASCVD risk and the potential impact of risk-lowering interventions
por: Mendez, Keegan, et al.
Publicado: (2022)

MAFLD and ASCVD: Plasma Heparin Cofactor II Activity as an Anti-liver Fibrosis Biomarker
por: Shimabukuro, Michio
Publicado: (2023)

Highlights in ASCVD Primary Prevention for 2021
por: Polonsky, Tamar S., et al.
Publicado: (2022)

IMPACT OF THE COVID-19 PANDEMIC ON THE MANAGEMENT OF RISK FACTORS IN PATIENTS WITH ASCVD
por: Karalis, Dean, et al.
Publicado: (2023)

COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD
por: Myers, Kelly D., et al.
Publicado: (2021)

Combination of Endoglin and ASCVD Risk Assessment Improves Carotid Subclinical Atherosclerosis Recognition
por: Li, Qiaowei, et al.
Publicado: (2020)

RELATION OF 10-YEAR ASCVD RISK SCORE WITH SEVERE COVID-19 OUTCOMES
por: Arif, Yousif, et al.
Publicado: (2022)

Comparison of Framingham Cardiovascular Risk Criteria and ASCVD Score in Iranian Obese Patients
por: Hasani-Ranjbar, Shirin, et al.
Publicado: (2023)

Metabolomics profile and 10-year atherosclerotic cardiovascular disease (ASCVD) risk score
por: Dehghanbanadaki, Hojat, et al.
Publicado: (2023)

External validation of the ACC/AHA ASCVD risk score in a Colombian population cohort
por: Rodríguez-Ariza, Carlos Daniel, et al.
Publicado: (2023)

Health Literacy is Essential to ASCVD Prevention in Youth
por: Mann, Harnoor K., et al.
Publicado: (2023)

Role of New Potential Biomarkers in the Risk of Thromboembolism in Atrial Fibrillation
por: Pezzo, Mario Piergiulio, et al.
Publicado: (2022)

10-year ASCVD risk is positively correlated with depressive symptoms in a large general population
por: Sun, Guo-Zhe, et al.
Publicado: (2019)

Identifying Opportunities for Impact of Community-Based Pharmacist-Led Biometric Health Screenings on ASCVD Risk
por: Newell, Bradley J., et al.
Publicado: (2023)

A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD
por: Srivastava, Rai Ajit K.
Publicado: (2023)

MBOAT7 rs641738 (C>T) is associated with NAFLD progression in men and decreased ASCVD risk in elder Chinese population
por: Xu, Xiaoyi, et al.
Publicado: (2023)

Effects of weight change on apolipoprotein B-containing emerging atherosclerotic cardiovascular disease (ASCVD) risk factors
por: Dansinger, Michael L., et al.
Publicado: (2019)

Ten-year risk assessment for cardiovascular diseases using ASCVD risk estimator plus: outcomes from hypertension and diabetes patients
por: Osoro, Ian, et al.
Publicado: (2023)

Utility of coronary artery calcium in refining 10-year ASCVD risk prediction using a Thai CV risk score
por: Tiansuwan, Noppanat, et al.
Publicado: (2023)

Inverse Association between Educational Status and Coronary CT Calcium Scores: Should We Reflect This in Our ASCVD Risk Assumptions?
por: Dienhart, Christiane, et al.
Publicado: (2023)

Chinese ASCVD risk equations rather than pooled cohort equations are better to identify macro- and microcirculation abnormalities
por: Li, Qiaowei, et al.
Publicado: (2020)

Mean platelet volume: a potential biomarker of the risk and prognosis of heart disease
por: Choi, Dong-Hyun, et al.
Publicado: (2016)

Emerging Role of Enhancer RNAs as Potential Diagnostic and Prognostic Biomarkers in Cancer
por: Panahi-Moghadam, Somayeh, et al.
Publicado: (2022)

Expanding statin use for prevention of ASCVD in Indians: Reasoned and simplified proposals
por: Enas, Enas A., et al.
Publicado: (2020)

Exosomal miRNAs as potential biomarkers of cardiovascular risk in children
por: Khalyfa, Abdelnaby, et al.
Publicado: (2014)

Skin disorders in Parkinson’s disease: potential biomarkers and risk factors
por: Ravn, Astrid-Helene, et al.
Publicado: (2017)

979. BMI and ASCVD Risk Score Changes in Virologically Suppressed Patients with HIV Switching from TDF to TAF Containing ART
por: Schafer, Jason J, et al.
Publicado: (2019)

615. Overlooking those at Intermediate Risk? ASCVD Prevention Measures among People Living with HIV at an Urban Academic Medical Center
por: Liotta, Mark, et al.
Publicado: (2020)

Sex-specific performance of the ASCVD pooled cohort equation risk calculator as a correlate of coronary artery calcium in Kampala, Uganda
por: Kentoffio, Katherine, et al.
Publicado: (2022)

Long-Term Outcomes Associated with NAFLD, ASCVD, and All-Cause Mortality of Patients with Metabolic Syndrome
por: Jitrukthai, Suchanart, et al.
Publicado: (2022)

Role of biomarkers in risk stratification of acute coronary syndrome
por: Nagesh, C.M., et al.
Publicado: (2010)

Subclinical Hypertension-Mediated Organ Damage (HMOD) in Hypertension: Atherosclerotic Cardiovascular Disease (ASCVD) and Calcium Score
por: Rizzoni, Damiano, et al.
Publicado: (2022)

The role of biomarkers in the diagnosis and risk stratification of acute coronary syndrome
por: Chacko, Sanoj, et al.
Publicado: (2017)

Apolipoprotein E polymorphisms contribute to statin response in Chinese ASCVD patients with dyslipidemia
por: Zhang, Lei, et al.
Publicado: (2019)

Analisi di costo-utilità di evolocumab in pazienti con ASCVD in Italia
por: Marcellusi, Andrea, et al.
Publicado: (2021)

ASCVD risk stratification modifies the effect of HbA1c on cardiovascular events among patients with type 2 diabetes mellitus with basic to moderate risk
por: Zhang, Hongmei, et al.
Publicado: (2020)

High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk
por: Hafiane, Anouar, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_99v23alvpcij2ui7idosq96vm6